关于伊克维亚印度尼西亚

Driving Healthcare Performance in Indonesia

Established in 1990, IQVIA Indonesia offers a broad range of clinical and commercial services and solutions. Our commercial services started with market data and expanded into market research. We recently launched new audits aligned to current market dynamics.

我们提供全方位的开发服务，包括临床监测，患者招聘，现场管理，质量管理和医疗服务。我们的员工包括来自各种背景的经验丰富的临床试验监视器，包括医生，药剂师和生物医学科学家。

Indonesia Healthcare Outlook

自2014年印度尼西亚的普遍健康覆盖范围（UHC）计划启动以来，大约有1.8亿人招募lol买外围用什么软件了该国2.59亿人口的70％。到2019年，预计UHC入学率将达到100％。印度尼西亚的私人保险渗透率估计为8％或2000万人。随着越来越多的患者获得医疗保健，UHC可以推动公立医院以及参与私人医院的住院和门诊服务的需求。lol买外围用什么软件

Indonesia’s growing economy is expanding the middle class. Both rising incomes and the UHC program are expected to accelerate private sector investment in healthcare.

Primary health care is the front line of the UHC program administered by the Ministry of Health. Patient volume is expected to increase significantly between now and 2019. Despite improvements at government-owned hospitals, the increased volume is expected to result in longer waits for patients. Those with private insurance or the ability to pay out-of-pocket can expect shorter wait periods; those with the need for specialist doctors will likely go to private hospitals.

Biopharmaceutical Market Overview

The generic segment remains the most attractive. Local and multinational drug manufacturers are expecting consumption to continue to increase as a result of UHC-driven demand from government-run and participating private hospitals. Indonesia accounts for the highest proportion of ASEAN over-the-counter (OTC) medicine sales, 40 percent, indicating the propensity of domestic consumers for self-medication. OTC manufacturers can expect growing demand during the medium to long terms.

Middle-class Indonesian consumers increasingly prefer branded generics to lower-cost, unbranded drugs, creating opportunities for generic manufacturers and importers. With the increase access to healthcare through UHC and economic improvement, people are likely to move away from self-treatment to seek treatment in clinic and hospitals.

为了满足不断增长的需求，印尼政府一直在推动自给自足的药物生产，并向外国投资开放制药行业。印尼政府打算通过使用生物仿制药和疫苗来获得肿瘤学，心血管，糖尿病和传染病领域中更多负担得起的药物来解决lol买外围用什么软件重大健康状况。提高临床试验能力是回答该国需要更具创新医疗保健解决方案来满足这些需求的一种方法。lol买外围用什么软件

Regulatory Environment for Clinical Development

政府正在支持将印度尼西亚的生物制药和医疗设备行业从重点放在制造/生产上的努力，更加基于研发和创新。早期与当地监管机构的互动对于包括印度尼西亚在内的临床发展计划中的成功至关重要。

有一些类型的研究不需要监管机构批准，例如疾病或产品注册表研究；lol买外围用什么软件健康经济和结果研究；以及用于监管和营销目的的本地数据生成。这些类型的研究在该国仍然非常需要采取公共卫生政策。lol买外围用什么软件

Among recent significant regulatory changes are:

• Presidential Instruction No. 6 year 2016 (re-emphasized by the Ministry of Health Decree No. 17 in 2017) provides direction for the biopharma and medical devices to support improvement in health services under UHC.
• Head of National Agency of Drug and Food Control Decree No. 21 (2015) regulating clinical trial conduct for pre- and post-marketing (phase I to IV) studies inclusive of vaccine development guidelines.
• 国家药物和食品控制法令局长第16号（2015年）根据地方和外国研究机构或制药行业规定新药开发和制造。
• Head of National Agency of Drug and Food Control Decree No. 17 (2015) provides guidance for research and development of biosimilars.

疾病患病率

非传染性疾病（NCD）约占印度尼西亚所有死亡人数的三分之二。四个主要的NCD是心血管疾病，糖尿病，癌症和慢性呼吸道疾病。严重的传染病是结核病，艾滋病毒/艾滋病，腹泻，疟疾，肺炎，肝炎和热带疾病，例如狂犬病，麻风病，丝虫病，嗜动物症，嗜血杆菌，炭疽病，炭疽病，yaws。所有这些都依赖于政府的战略健康议程。lol买外围用什么软件

商业解决方案

• Information: Sales Audit and Prescription Audit
• Primary Market Research: Market Assessment, Brand Tracking and Customer Satisfaction
• 分析：细分和定位，销售部队的规模和结构，领土对齐和激励补偿

临床研究经验和服务

我们在传染病，呼吸道，心血管和代谢疾病，精神病学和风湿病方面具有丰富的经验。我们的经验范围从早期发展到观察性和第4阶段研究，包括现实世界的见解，并为研究人员发起的试验提供了专门的产品（IIT）。王者荣耀kpl外围投注